IGF1R and Ewing sarcoma: Insulin-like growth factor 1 receptor (IGF-1R) was a candidate as a treatment target of Ewing sarcoma, and early-phase clinical trials of IGF-1F inhibitors, especially of figitumumab, showed a modest response among recurrent/metastatic Ewing sarcoma patients, including complete remission [110,111,112].